Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.
Also called NCT01704079
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 216 participants
- Sponsor
- OPKO IP Holdings II, Inc.
- Registry
-
NCT01704079
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01704079. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2016-08-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
- Condition
- Chronic Kidney Disease
- Condition
- Hyperparathyroidism, Secondary
- Condition
- Vitamin D Deficiency
- Intervention (Drug)
- CTAP101 30 μg capsules
- Intervention (Other)
- Sugar pill to CTAP101 30 μg capsules
- Lead sponsor
- OPKO IP Holdings II, Inc.
Record details
- Record id
cardio:ct-nct01704079- Content hash
d2dc54234c535d31b8098cf7c60aa47ccca9d0c00be21191367d43c899b0b2b1